top of page

Overview

Critical Innovations is currently developing multiple medical devices toward regulatory clearance. The company focuses on task-shifting evidence-based interventions to earlier echelons of care and more general specialty levels, to simplify management and allow for rapid provision in emergency and combat environments. To date, the company has worked under more than 20 different Department of Defense awards from all three military branches charged with medical technology development (i.e. U.S. Army, Air Force, and Navy), including such agencies as the Air Force Medical Support Agency; Army Medical Research and Development Command; Defense Health Agency; and, Office of Naval Research. Contract types have included Small Business Innovation Research (SBIR), Joint Warfighter, and Other Transactional Authority. As a prime contractor, Critical Innovations currently has a 100% transition rate from Phase I to Phase II, as well as Phase II to Phase III, for all eligible SBIR programs.

Our Devices

Search

Critical Innovations
- May 27, 2022
- 1 min read

USAMMDA’s WEMT PMO Visits Critical Innovations

This month, Critical Innovations was happy to host seven visitors from the U.S. Army Medical Materiel Development Activity’s (USAMMDA) Warfighter Expeditionary Medicine and Treatment (WEMT) PMO at the company’s Los Angeles facility. USAMMDA’s WEMT PMO leads the development and fielding of medical devices, drugs, and biologics that fulfill the unmet requirements identified by the military end-users. The site visit was led by Ms. Christine Parker, Project Manager of WEMT PMO.

The WEMT PMO reviewed the progress of devices being developed by Critical Innovations in three separate product areas:

· Burn Treatment and Skin Repair (BTSR)

· Noncompressible Hemorrhage Control (NHC)

· Temporary Corneal Repair (TCR)

“It was a pleasure hosting this team of DOD [Department of Defense] professionals and working with them towards the goal of developing innovative solutions to address catastrophic injuries for the Warfighter,” said Dr. Ross Donaldson, President & CEO of Critical Innovations. “We received very useful feedback and look forward to continued interactions with USAMMDA, as we together work to improve care for injured patients.”

Recent Posts

Successful porcine safety trial of the F.O.A.M.™ device published in Military Medicine

Severe intra-abdominal bleeding currently requires operative treatment by trained surgeons, while Critical Innovations' patented F.O.A.M.™ technology task-shifts to allow earlier abdominal hemostasis

Critical Innovations signs CRADA with DEVCOM CBC

Critical Innovations is happy to announce that it recently signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Chemical Biologica

Critical Innovations signs new CRADA with Navy medicine

Critical Innovations signed a new Cooperative Research and Development Agreement (CRADA) with the Naval Medical Center San Diego / Navy Medicine Readiness and Training Command San Diego. The company i

bottom of page